所有图片(1)
选择尺寸
变更视图
25 MG
$174.00
About This Item
经验公式（希尔记法）:
C29H26ClFN4O4S
CAS号:
分子量:
581.06
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
推荐产品
描述
AldrichCPR
表单
solid
SMILES字符串
CS(=O)(CCNCC1=CC=C(C2=CC=C3N=CN=C(C3=C2)NC4=CC=C(C(Cl)=C4)OCC5=CC=CC(F)=C5)O1)=O
InChI
1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)
InChI key
BCFGMOOMADDAQU-UHFFFAOYSA-N
基因信息
human ... EGFR(1956) , ERBB2(2064)
正在寻找类似产品? 访问 产品对比指南
其他说明
请注意，Sigma-Aldrich将此产品作为一系列独特化学品的一部分提供给早期发现的研究人员。Sigma-Aldrich不会收集该产品的分析数据。买方承担确认产品标识和纯度的责任。所有销售均为最终销售。
尽管SIGMA-ALDRICH的标准条款和条件以及SIGMA-ALDRICH和买方之间的协议中包含所有合同条款，但无论是在法律、交易过程、执行过程中的行为、以及贸易或其他方面的使用等过程中，SIGMA-ALDRICH按“原样”销售此产品并且并对此产品不作任何陈述或担保，包括：(A)适销性担保；(B)特定用途适用性担保；或(C)未侵犯第三方知识产权担保。
尽管SIGMA-ALDRICH的标准条款和条件以及SIGMA-ALDRICH和买方之间的协议中包含所有合同条款，但无论是在法律、交易过程、执行过程中的行为、以及贸易或其他方面的使用等过程中，SIGMA-ALDRICH按“原样”销售此产品并且并对此产品不作任何陈述或担保，包括：(A)适销性担保；(B)特定用途适用性担保；或(C)未侵犯第三方知识产权担保。
警示用语：
Warning
危险声明
危险分类
Aquatic Chronic 4 - Eye Irrit. 2 - Lact.
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
其他客户在看
Shota Tanaka et al.
Scientific reports, 9(1), 139-139 (2019-01-16)
Intratumoural heterogeneity underlies tumour escape from molecularly targeted therapy in glioblastoma. A cell-based model preserving the evolving molecular profiles of a tumour during treatment is key to understanding the recurrence mechanisms and development of strategies to overcome resistance. In this
Aleksandra Simiczyjew et al.
Cancers, 10(9) (2018-09-20)
Triple-negative breast cancer (TNBC) is the most challenging subtype to treat due to the lack of estrogen receptor, progesterone receptor, and HER2 expression, which excludes the usage of directed targeted therapy against them. Promising therapeutic targets are the hepatocyte growth
Tushar Piyush et al.
Cell death and differentiation, 24(11), 1937-1947 (2017-07-22)
Epidermal growth factor receptor (EGFR) is an important regulator of epithelial cell growth and survival in normal and cancerous tissues and is a principal therapeutic target for cancer treatment. EGFR is associated in epithelial cells with the heavily glycosylated transmembrane
Melinda Halasz et al.
Science signaling, 9(455), ra114-ra114 (2016-11-24)
Signal transduction networks are often rewired in cancer cells. Identifying these alterations will enable more effective cancer treatment. We developed a computational framework that can identify, reconstruct, and mechanistically model these rewired networks from noisy and incomplete perturbation response data
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Baselga J, et al.
The Lancet, 379(9816), 633-640 (2012)
Active Filters
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持
